Thursday, June 23, 2016 12:56:41 PM
Green Cures & Botanical Distribution (GRCU), one on HEMP's consulting clients, issued a PR this morning (6/23/16) via InvestorsHub Newswire. Here's the pertinent section of the PR, followed by a link to the complete release:
Quote:
Dear Shareholders:
As previously announced on March 28, 2016, Green Cures & Botanical Distribution Inc. entered into a consulting agreement with Hemp Inc’s Industrial Hemp and Medical Marijuana Consulting Company (IHMMCC) per a signed consulting agreement dated February 20, 2016.
In light of recent events surrounding Bruce Perlowin, Hemp Inc’s CEO, Green Cures & Botanical Distribution Inc feels it’s in the best interest of GRCU and its shareholders to rescind the contract as well as the restricted shares that were issued to Hemp Inc..
GRCU would like to assure its shareholders and investors that it was a consulting agreement only; Mr. Perlowin did not serve as a member of the board in any way. GRCU is one of many companies who sought out the experience and vast access to resources in the industrial hemp and medical marijuana industries through Mr. Perlowin and his consulting company, IHMMCC. GRCU will continue its course in this sector without Mr. Bruce Perlowin and his consulting services, however, is grateful for the introductions to distribution opportunities and industry information.
http://ih.advfn.com/p.php?pid=nmona&article=71802762
BTW: When this consulting deal was announced, GRCU paid HEMP 13M shares of its stock, which was orthe about $0.035 at the time. These received shares accounted for about $455K of HEMP's $743K of the claimed revenues in 1Q/16. The remaining revenues were the value of the shares of FUTL received at the signing of that consulting agreement in early February.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM